While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.

The transition from academia to entrepreneurship is most successful when the focus shifts from pure science or technology to solving a tangible, pre-existing clinical problem. This ensures market interest, clinical adoption, and ultimately, patient impact from the outset.

Instead of tackling their grand vision head-on, Guardant started with a more solvable problem: therapy selection for late-stage cancer. They planned a roadmap to scale their technology 10x at each step, progressively unlocking larger and more complex markets.

Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.

AdaptDx plans to first target specific, high-need clinical conditions like heart failure to secure FDA approval and reimbursement. This clinical validation and revenue stream will then fund the miniaturization and expansion into the broader consumer health and wellness market, bridging the gap between medical care and daily life.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

Many companies fail by building a technology and then searching for a problem. VedaBio exemplifies the opposite approach: first defining the "perfect product" for a specific need (urgent care testing), and then applying the right technology to build it.

Instead of pursuing broad, expensive trials common in areas like cardiovascular disease, smaller biotechs can succeed by focusing. They use imaging, genetics, and proximal biomarkers to identify and enroll a highly specific patient population whose disease is still modifiable, enabling much smaller and more targeted clinical trials.